BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 10874063)

  • 1. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
    Schulman S; Lindmarker P
    N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.
    Schulman S; Rhedin AS; Lindmarker P; Carlsson A; Lärfars G; Nicol P; Loogna E; Svensson E; Ljungberg B; Walter H
    N Engl J Med; 1995 Jun; 332(25):1661-5. PubMed ID: 7760866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.
    Sørensen HT; Mellemkjaer L; Steffensen FH; Olsen JH; Nielsen GL
    N Engl J Med; 1998 Apr; 338(17):1169-73. PubMed ID: 9554856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
    N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of cancers associated with venous thromboembolism.
    Sørensen HT; Mellemkjaer L; Olsen JH; Baron JA
    N Engl J Med; 2000 Dec; 343(25):1846-50. PubMed ID: 11117976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.
    Kyrle PA; Minar E; Hirschl M; Bialonczyk C; Stain M; Schneider B; Weltermann A; Speiser W; Lechner K; Eichinger S
    N Engl J Med; 2000 Aug; 343(7):457-62. PubMed ID: 10950667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis.
    van Dongen CJ; Vink R; Hutten BA; Büller HR; Prins MH
    Arch Intern Med; 2003 Jun; 163(11):1285-93. PubMed ID: 12796064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
    Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
    Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.
    Prandoni P; Villalta S; Bagatella P; Rossi L; Marchiori A; Piccioli A; Bernardi E; Girolami B; Simioni P; Girolami A
    Haematologica; 1997; 82(4):423-8. PubMed ID: 9299855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.
    Prandoni P; Lensing AW; Büller HR; Cogo A; Prins MH; Cattelan AM; Cuppini S; Noventa F; ten Cate JW
    N Engl J Med; 1992 Oct; 327(16):1128-33. PubMed ID: 1528208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    Bergqvist D; Agnelli G; Cohen AT; Eldor A; Nilsson PE; Le Moigne-Amrani A; Dietrich-Neto F;
    N Engl J Med; 2002 Mar; 346(13):975-80. PubMed ID: 11919306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.